Emery-Dreifuss muscular dystrophy (EDMD) is characterized by muscular weakness and atrophy, with early joint contractures and cardiomyopathy.
Comprehensive, easy-to-understand information about this condition
How we create this content →Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Emery-Dreifuss muscular dystrophy
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 1 company has orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning Emery-Dreifuss muscular dystrophy
Updated Feb 6, 2026
The EU-funded DREAMS project, now including University College London, aims to accelerate the discovery of treatments for rare neuromuscular disorders. By leveraging AI-based drug discovery and advanced screening methods, the project targets five specific diseases, including Duchenne muscular dystrophy and centronuclear myopathy.